首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Evaluation of analgesic effect of tapentadol, a central novel analgesic versus tramadol, a widely used opioid analgesic in treatment of low back pain: a randomized controlled trial
【24h】

Evaluation of analgesic effect of tapentadol, a central novel analgesic versus tramadol, a widely used opioid analgesic in treatment of low back pain: a randomized controlled trial

机译:评价他喷他多(一种主要的新型镇痛药与曲马多(一种广泛使用的阿片类镇痛药)在治疗下背痛中的镇痛作用):一项随机对照试验

获取原文
       

摘要

Background: The objective of the study was to compare efficacy and tolerability (safety) of tapentadol with tramadol in the treatment of low back pain. Methods: The study was a prospective, randomized, single blinded, total 102 patients are recruited for study in which 44 patients are prescribed (50mgtwice daily) tapentadol and 58 patients prescribed (50mg twice daily) tramadol for 4 weeks. Follow-up was done on days 7, 14, 28 and 4 week after stoppage of treatment. Assessment of improvement were performed by Indian Health Assessment Questionnaire Disability Index (Indian HAQDI), Visual Analogue Scale (VAS), Numerical Rating Scale (NRS) and measurement of Pain Relief Rate (PRR). Adverse events were recorded. Results: Scores in Indian HAQDI, VAS and NRS improved significantly in both groups in the last visit but more so with tapentadol. PRR was reasonably higher with tapentadol [27(n=44)61.36%] patients experiencing significant to complete pain relief at the end of the study, compared to tramadol [25(n=58) 43.10%]. Adverse effects was less in tapentadol group [15(n=44)34.09%] versus 33(n=58)56.89%], p Conclusion: Tapentadol has better sustained efficacy and tolerability than tramadol in low back pain.
机译:背景:本研究的目的是比较他喷他多与曲马多在治疗下背痛中的疗效和耐受性(安全性)。方法:该研究是一项前瞻性,随机,单盲的研究,共招募102例患者,其中44例处方(每日50mg两次)他喷他多和58例处方(每日50mg每天两次)曲马多4周。在停药后第7、14、28和4天进行随访。通过印度健康评估问卷残疾指数(Indian HAQDI),视觉模拟量表(VAS),数字量表(NRS)和疼痛缓解率(PRR)的测量来评估改善情况。记录不良事件。结果:在最后一次访视时,两组的印度HAQDI,VAS和NRS得分均显着改善,而他喷他多则更为明显。与曲马多相比,他喷他多[27(n = 44)61.36%]的患者在研究结束时显着完全缓解疼痛的患者的PRR相对较高[25(n = 58)43.10%]。他喷他多组的不良反应较少[15(n = 44)34.09%],而33(n = 58)56.89%],p结论:在腰背痛中,他喷他多具有比曲马多更好的持续疗效和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号